EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
Exuma Biotech has raised $41.0M in total funding. The most recent round was Series B. The last funding was announced in December 2021.
Exuma Biotech's investors include BioAtla, MSD Partners, Americo Financial Life and Annuity, Shanghai Sinobioway Sunterra Biotechnology, SunTerra Capital.
Exuma Biotech is headquartered in Grand Cayman, Cayman Islands.
EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
Exuma Biotech is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Exuma Biotech — Funding & Investors." VCBacked, December 21, 2021, https://www.vcbacked.co/company/exuma-biotech. Accessed August 13, 2026.
VCBacked. (2021). Exuma Biotech — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/exuma-biotech
{{cite web |title=Exuma Biotech — Funding & Investors |url=https://www.vcbacked.co/company/exuma-biotech |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated